CAJ | 학술논문

目的：探讨阿托伐他汀联合万爽力治疗冠心病心绞痛患者的临床应用价值。方法：2013年6月-2014年6月收治冠心病心绞痛患者116例，采用随机数字表法分为观察组和对照组各58例。两组患者均积极给予吸氧、利尿剂、β受体拮抗剂、硝酸酯制剂、钙拮抗剂等常规治疗，对照组在常规治疗的基础上给予万爽力(20 mg/次，3次/d)治疗，观察组给予阿托伐他汀(10 mg/次，1次/d)联合万爽力(20 mg/次，3次/d)治疗，4周为1个疗程。观察并比较两组患者临床疗效、治疗前后心绞痛发作情况以及治疗期间不良反应发生情况。结果：疗程结束后，观察组的显效率和总有效率分别为67.24%和89.66%，均明显高于对照组的53.45%和84.48%，差异均具有统计学意义(P＜0.05)；治疗后，两组患者心绞痛发作次数及持续时间均明显降低和缩短(P＜0.05)，以观察组降低和缩短程度更明显(P＜0.05)；两组患者均未发生药物相关的严重不良反应。结论：阿托伐他汀联合万爽力治疗冠心病心绞痛患者疗效显著，无严重不良反应，安全性好，可积极应用于临床冠心病心绞痛的治疗。
목적：탐토아탁벌타정연합만상력치료관심병심교통환자적림상응용개치。방법：2013년6월-2014년6월수치관심병심교통환자116례，채용수궤수자표법분위관찰조화대조조각58례。량조환자균적겁급여흡양、이뇨제、β수체길항제、초산지제제、개길항제등상규치료，대조조재상규치료적기출상급여만상력(20 mg/차，3차/d)치료，관찰조급여아탁벌타정(10 mg/차，1차/d)연합만상력(20 mg/차，3차/d)치료，4주위1개료정。관찰병비교량조환자림상료효、치료전후심교통발작정황이급치료기간불량반응발생정황。결과：료정결속후，관찰조적현효솔화총유효솔분별위67.24%화89.66%，균명현고우대조조적53.45%화84.48%，차이균구유통계학의의(P＜0.05)；치료후，량조환자심교통발작차수급지속시간균명현강저화축단(P＜0.05)，이관찰조강저화축단정도경명현(P＜0.05)；량조환자균미발생약물상관적엄중불량반응。결론：아탁벌타정연합만상력치료관심병심교통환자료효현저，무엄중불량반응，안전성호，가적겁응용우림상관심병심교통적치료。
Objective:To explore the value of clinical application of atorvastatin combined with trimetazidine in treatment of patients with angina pectoris.Methods:116 patients with coronary heart disease and angina pectoris were selected from June 2013 to June 2014.They were randomly divided into the observation group and the control group with 58 cases in each group according to the random number table method.Two groups of patients were treated with conventional treatment,such as oxygen,diuretics,beta blockers,nitrates preparation,calcium antagonists and so on.The control group were treated with trimetazidine(20 mg/times,3 times/d) on the basis of conventional treatment.The observation group were treated with atorvastatin(10 mg/times,1 time/d) combined with trimetazidine(20 mg/times,3 times/d) treatment.4 weeks were one treatment course.We observed and compared the clinical curative effect,angina pectoris attack before and after treatment,the incidence of adverse reaction during treatment.Results:After the end of treatment,in the observation group,the significant effective rate and the total efficiency was 67.24% and 89.66%respectively,which were significantly higher than those of the control group of 53.45%and 84.48%with significant difference(P<0.05).After treatment,angina attack frequency and duration of the two groups were significantly lower(P<0.05);in the observation group,decrease was more obviously(P<0.05).Two groups of patients were not drug related serious adverse reaction.Conclusion:The value of clinical application of atorvastatin combined with trimetazidine in treatment of patients with angina pectoris is significant.There is no serious adverse reactions.The security is good.It can be actively used in clinical treatment of angina pectoris of coronary heart disease.